Home > About Us > Council & Committees > Council

Professor Henry Lik Yuen Chan

Henry Lik Yuen Chan

MBChB (CUHK), MD (CUHK), FRCP (Edin), FRCP (Lond), FHKCP, FHKAM (Med)

Prof. Henry L. Y. Chan was graduated from The Chinese University of Hong Kong (CUHK) and obtained his Doctor of Medicine with commendation in 2001. He has completed the Executive Master of Business Administration degree in CUHK in 2014. He is currently Head of Division of Gastroenterology and Hepatology, Director of Institute of Digestive Disease, Director of Center for Liver Health, Director of Office of Global Engagement, and Assistant Dean (External Affairs) of Faculty of Medicine, CUHK. He is the course director of Master of Science in Gastroenterology, CUHK.

Prof. Chan was the President of the Hong Kong Association for the Study of Liver Diseases from 2005 to 2009. He is the coordinating editor for Journal of Gastroenterology and Hepatology (official journal of Asian Pacific Association of Gastroenterology), and an associate editor of Journal of Hepatology (official journal of European Association for the Study of the Liver), Hepatology International (official journal of Asian Pacific Association for the Study of the Liver) and Seminars in Liver Disease. He is the co-chairman of the Joint European-Latin American Clinical Practice Guideline panel for non-invasive tests for liver disease evaluation in 2015 and a member of the writing committee of the Asian-Pacific management guideline for chronic hepatitis B in 2012 and 2015. Prof. Chan is also the co-chairman of the Strategic and Technical Committee on viral hepatitis of the Western Pacific Regional Office of World Health Organization. He was award as one of the Ten Outstanding Young Persons in Hong Kong in 2008 in recognition of his professional excellence and contribution to the community.

Prof. Chan is a key investigator in over 25 international trials on antiviral treatment of chronic hepatitis B and C, and is the global lead author in publications on peginterferon-alfa, peginterferon-lambda, telbivudine, and tenofovir for the treatment of viral hepatitis B. He has received numerous local, national and international research awards. His research team was awarded a Second Class National Award for Science and Technology Progress and a First-class Ministry of Health Higher Education Outstanding Scientific Research Output Award (Scientific and Technological Progress Award) in China in 2012.

Information for